CorMedix (CRMD) Total Non-Current Liabilities (2013 - 2026)

CorMedix (CRMD) posted Total Non-Current Liabilities of $6.0 million for Q4 2021, up 53.06% sequentially from $3.9 million in Q2 2017.

CorMedix (CRMD) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends

CorMedix has reported Total Non-Current Liabilities for 5 years, with the latest figure at $6.0 million in Q4 2021.

Quarterly Total Non-Current Liabilities changed N/A year-over-year to $6.0 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $6.0 million (changed N/A YoY) and the FY2021 annual result came in at $6.0 million, changed N/A from the prior year.
Total Non-Current Liabilities climbed to $6.0 million in Q4 2021 per CRMD's latest filing, from $3.9 million in the prior quarter.
Over five years, Total Non-Current Liabilities peaked at $6.0 million in Q4 2021 and troughed at $3.9 million in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	5.92 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	7.74 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	40.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	3.92 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.88 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	4.20 Bn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	724.15 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	1.17 Bn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	9.32 Bn
10	CorMedix	645.20 Mn	388.51 Mn	77.13 Mn	440.91 Mn

Download Data